| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/26/2010 | CA2319255C Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy |
| 01/26/2010 | CA2299470C Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation |
| 01/26/2010 | CA2213567C Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor |
| 01/26/2010 | CA2213500C Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 01/26/2010 | CA2185347C A carrier for hydrophobic drugs and a pharmaceutical composition based thereon |
| 01/21/2010 | WO2010009451A2 Long-acting injectable analgesic formulations for animals |
| 01/21/2010 | WO2010009449A2 Extended release pharmaceutical formulations of s-adenosylmethionine |
| 01/21/2010 | WO2010009432A1 Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| 01/21/2010 | WO2010009288A1 Compositions and uses of antiviral active pharmaceutical agents |
| 01/21/2010 | WO2010009186A1 Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein |
| 01/21/2010 | WO2010009146A1 Nanoclusters for delivery of poorly water soluble drug nanoparticles |
| 01/21/2010 | WO2010009116A2 Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| 01/21/2010 | WO2010009111A2 A drug depot implantable within a synovial joint |
| 01/21/2010 | WO2010009075A1 Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds |
| 01/21/2010 | WO2010009065A2 Amphipathic peptide compositions |
| 01/21/2010 | WO2010009056A2 Pain relieving patch |
| 01/21/2010 | WO2010008995A2 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| 01/21/2010 | WO2010008876A2 Method for preparation of micellar hybrid nanoparticles for therapeutic and diagnostic applications and compositions thereof |
| 01/21/2010 | WO2010008719A2 Oral pharmaceutical formulations of vla-4 antagonists |
| 01/21/2010 | WO2010008601A1 Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| 01/21/2010 | WO2010008600A1 Topical drug delivery system |
| 01/21/2010 | WO2010008519A2 In vitro diagnostic markers comprising carbon nanoparticles and kits |
| 01/21/2010 | WO2010008244A2 Pharmaceutical preparation |
| 01/21/2010 | WO2010008224A2 Fast-dissolving amlodipine tablets of improved stability and a method of manufacture thereof |
| 01/21/2010 | WO2010008203A2 Pharmaceutical formulation containing a calcium channel blocker |
| 01/21/2010 | WO2010008135A1 Oral soft capsule of aceclofenac having improved stability |
| 01/21/2010 | WO2010008001A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | WO2010007604A2 Inhalable microparticles, and methods for the production thereof |
| 01/21/2010 | WO2010007565A2 Drug delivery garment |
| 01/21/2010 | WO2010007494A2 New composition for the treatment of ecchymotic pigmentations |
| 01/21/2010 | WO2010007447A1 Process for improving crystallinity |
| 01/21/2010 | WO2010007446A1 Process for improving crystallinity of fluticasone particles |
| 01/21/2010 | WO2010007312A2 Method of manufacturing cellular films directly |
| 01/21/2010 | WO2010007252A2 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | WO2010007232A1 Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compositions |
| 01/21/2010 | WO2010007141A1 Sugar micro/nanofoams |
| 01/21/2010 | WO2010007016A1 Method for manufacturing medicinal compounds containing dabigatran |
| 01/21/2010 | WO2010006929A1 Pharmaceutical compositions comprising levetiracetam |
| 01/21/2010 | WO2010006753A2 Silicon dioxide nanoparticles and their use for vaccination |
| 01/21/2010 | WO2010006708A1 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 01/21/2010 | WO2010006697A2 Powders for reconstitution |
| 01/21/2010 | WO2010006612A2 Canker sore patch |
| 01/21/2010 | WO2010006451A1 Dosage form containing a statin |
| 01/21/2010 | WO2010006442A1 Articles of manufacture releasing an active ingredient |
| 01/21/2010 | WO2009146147A3 Target-responsive hydrogels |
| 01/21/2010 | WO2009144744A3 Compositions comprising euphorbia prostrata and process of preparation thereof |
| 01/21/2010 | WO2009143845A3 Flavor impregnation of a chewing gum core |
| 01/21/2010 | WO2009142852A3 Process for manufacturing flowable powder drug compositions |
| 01/21/2010 | WO2009137689A3 Delivery of nucleic acid complexes from particles |
| 01/21/2010 | WO2009136408A4 Synergistic pharmaceutical cocrystals |
| 01/21/2010 | WO2009134929A3 Compositions and methods for treating digestive disorders |
| 01/21/2010 | WO2009134728A3 Compositions and methods for treating multiple sclerosis |
| 01/21/2010 | WO2009134092A3 Poorly soluble drug-containing release-controlled polymeric nanoparticle formulation |
| 01/21/2010 | WO2009134086A3 Pharmaceutical formulation for treatment of cardiovascular disease |
| 01/21/2010 | WO2009134079A3 Pharmaceutical formulation |
| 01/21/2010 | WO2009134057A3 Pharmaceutical formulation containing angiotensin-ii receptor blocker |
| 01/21/2010 | WO2009134056A3 Pharmaceutical formulation |
| 01/21/2010 | WO2009134053A3 Pharmaceutical composition containing thiazide-based compound with controlled release and angiotensin-ii-receptor blocker |
| 01/21/2010 | WO2009129510A3 Sulindac formulations in a biodegradable material |
| 01/21/2010 | WO2009129433A3 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| 01/21/2010 | WO2009123759A3 Therapeutic uses of biocompatible biogel compositions |
| 01/21/2010 | WO2009120885A3 Stabilizing lipid compositions for oral pharmaceutical agents |
| 01/21/2010 | WO2009117127A3 Nerve repair with a hydrogel and optional adhesive |
| 01/21/2010 | WO2009115160A3 Chewing composition and the use thereof |
| 01/21/2010 | WO2009114614A3 Compositions and methods for controlled delivery of inhibitory ribonucleic acids |
| 01/21/2010 | WO2009113091A3 Pharmaceutical compositions comprising valsartan |
| 01/21/2010 | WO2009104916A9 Pharmaceutical formulations for the treatment of cardiovascular diseases |
| 01/21/2010 | WO2009074552A3 Multi-zone films |
| 01/21/2010 | WO2009056569A9 Lh liquid formulations |
| 01/21/2010 | WO2009053741A3 Novel formulation |
| 01/21/2010 | WO2009043395A9 Pharmaceutical composition |
| 01/21/2010 | WO2009026315A3 Use of carbon nanotube for drug delivery |
| 01/21/2010 | WO2008154234A3 Extended release formulation of nevirapine |
| 01/21/2010 | WO2008144730A3 Stable pharmaceutical formulation for a dpp-iv inhibitor |
| 01/21/2010 | US20100016790 Treatment And Pre-Treatment Device, And Manufacturing Method Therefor, Involving Nitric Oxide |
| 01/21/2010 | US20100016549 Peyer's patch and/or m-cell targeting ligands |
| 01/21/2010 | US20100016448 Flashmelt oral dosage formulation |
| 01/21/2010 | US20100016428 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events |
| 01/21/2010 | US20100016267 Pharmaceutical compositions for administraton to a sinus |
| 01/21/2010 | US20100015671 Cyclic maltosylmaltose, cyclic maltosymaltose-forming enzyme, their preparation and uses |
| 01/21/2010 | US20100015253 Treatment of nail infections with no |
| 01/21/2010 | US20100015240 Process for preparing microparticles containing bioactive peptides |
| 01/21/2010 | US20100015239 Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
| 01/21/2010 | US20100015238 Powder Compositions for Inhalation |
| 01/21/2010 | US20100015237 NSAID Delivery from Polyarylates |
| 01/21/2010 | US20100015235 Compositions and methods for treating multiple sclerosis |
| 01/21/2010 | US20100015234 Pharmaceutical preparations and their manufacture |
| 01/21/2010 | US20100015233 anti-parasitic compositions |
| 01/21/2010 | US20100015232 Nanoparticles for nucleic acid delivery |
| 01/21/2010 | US20100015231 Low swell, long-lived hydrogel sealant |
| 01/21/2010 | US20100015230 Bone Morphogenetic Protein Compositions |
| 01/21/2010 | US20100015229 Pharmaceutical compositions |
| 01/21/2010 | US20100015228 Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| 01/21/2010 | US20100015227 Dried electrified hydrocolloid gels having unique structure and porosity |
| 01/21/2010 | US20100015226 Bioresorbable hydrogel |
| 01/21/2010 | US20100015225 Solid dispersion of a neurokinin antagonist |
| 01/21/2010 | US20100015224 Programmable buoyant delivery technology |
| 01/21/2010 | US20100015223 Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion |
| 01/21/2010 | US20100015222 Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| 01/21/2010 | US20100015221 Orally rapid disintegrating tablet preparation comprising fat-soluble active ingredients |